Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV Genotype 1 and HIV-1: A Phase 3 study

Clinical Infectious Diseases

Volumn 59, Issue 11, 2014, Pages 1579-1587

  Dieterich, Douglas ^a   Rockstroh, Jürgen Kurt ^b   Orkin, Chloe ^c   Gutiérrez, Félix ^d   Klein, Marina B ^e   Reynes, Jacques ^f   Shukla, Umesh ^g   Jenkins, Alan ^h   Lenz, Oliver ⁱ   Ouwerkerk Mahadevan, Sivi ^j   Peeters, Monika ⁱ   De La Rosa, Guy ^g   Tambuyzer, Lotke ⁱ   Jessner, Wolfgang ⁱ  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Immunologische Ambulanz   (Germany)

^c ROYAL LONDON HOSPITAL   (United Kingdom)

^d MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^f GUI DE CHAULIAC HOSPITAL   (France)

^g Janssen Global Services Llc   (United States)

^h Janssen Research and Development   (United States)

ⁱ JANSSEN RESEARCH FOUNDATION   (Belgium)

^j JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

more..

Author keywords

Coinfection; Hepatitis C virus; Human immunodeficiency virus type 1; Simeprevir

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ENFUVIRTIDE; LOPINAVIR; MARAVIROC; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; RALTEGRAVIR; RILPIVIRINE; SIMEPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; FUSED HETEROCYCLIC RINGS; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN; SULFONAMIDE;

ADULT; AGED; ANEMIA; ANGINA PECTORIS; ARTICLE; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CYTOPENIA; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GENERAL CONDITION DETERIORATION; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; INTERVERTEBRAL DISK HERNIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MENTAL DISEASE; MIXED INFECTION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NONHUMAN; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PHOTOSENSITIVITY; PNEUMOTHORAX; PRIORITY JOURNAL; PRURITUS; RELAPSE; SIDE EFFECT; SPINE FRACTURE; SUNBURN; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; CLINICAL TRIAL; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; ISOLATION AND PURIFICATION; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SIMEPREVIR; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84918594340     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu675     Document Type: Article

References (24)

1. Andreoni M, Giacometti A, Maida I, Meraviglia P, Ripamonti D, Sarmati L. HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications. Eur Rev Med Pharmacol Sci 2012; 16: 1473-83.
2. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-41.
3. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50: 1387-96.
4. Reekie J, Gatell JM, Yust I, et al. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata. AIDS 2011; 25: 2259-68.
5. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50: 407-13.
6. Berenguer J, Rodriguez E, Miralles P, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2012; 55: 728-36.
7. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-48.
8. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-9.
9. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
10. Nunez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007; 23: 972-82.
11. Rodriguez-Torres M, Slim J, Bhatti L, et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials 2012; 13: 142-52.
12. Casey LC, Lee WM. Hepatitis C therapy update. Curr Opin Gastroenterol 2012; 28: 188-92.
13. Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010; 138: 913-21.
14. Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol 2012; 56: 1247-53.
15. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 1918-29.
16. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014; 146: 430-41.
17. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146: 1669-79.
18. Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2014; 384: 414-26.
19. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-13.
20. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. New Engl J Med 2011; 364: 2417-28.
21. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13: 597-605.
22. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159: 86-96.
23. Huisman MT, Snoeys J, Monbaliu J, Martens M, Sekar V, Raoof A. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. Hepatology 2010; 52: 461A.
24. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir with/without ribavirin for treating chronic HCV genotype 1 infection in prior null-responders to peginterferon/ribavirin and treatmentnaïve patients (COSMOS: a randomised study) [Epub ahead of print]. Lancet 2014.